Genome & Company announces first patient dosed in Phase 1/1b study of GEN-001, an immuno-oncology microbiome therapeutic, in combination with avelumab
* The first microbiome oncology therapeutic candidate developed by an Asia -based biotech successfully initiatesphase 1/1b clinical trial in the US, six months after its IND went into effect. * The first patient enrolled and treated at OHSU (Oregon Health & Science University Knight Cancer In...
Genome & Company receives FDA IND clearance for GEN-001, its first anti-cancer microbiome therapeutic
SEOUL, South Korea, April 20, 2020 /PRNewswire/ -- Genome & Company (KONEX: 314130), a biotechnology company developing innovative therapeutics in immune-oncology, announced today thatthe United States (US) Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) applic...
Genome & Company announces a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer
SEOUL, South Korea, Jan. 14, 2020 /PRNewswire/ -- Genome & Company (KONEX: 314130) is pleased to announce that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt,Germany and Pfizer Inc. to evaluate the safety, tolerability, biological and clinical ...
